🇺🇸 FDA

Intelligence · Clinical Pipeline

Phase III Pipeline Programs

Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Programs
5,427

Quick answer

NovaPharmaNews tracks 5,427 phase iii pharmaceutical pipeline programs from ClinicalTrials.gov. Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Top sponsors

Page 52 of 114

  1. Lorundrostat Placebo Tablets, Lorundrostat, Synacthen 0,25 mg/ml Injektionslösung, Lorundrostat

    Mineralys Therapeutics

    Uncontrolled and Resistant Hypertension

    phase 3 small molecule active

    1 trial

  2. Lorundrostat, Lorundrostat, Synacthen 0,25 mg/ml Injektionslösung, Lorundrostat Placebo tablet, Lorundrostat

    Mineralys Therapeutics

    Hypertension

    phase 3 small molecule active

    1 trial

  3. Losartan

    BRIGHT MINDS BIOSCIENCES INC.

    Glomerulonephritis, IGA

    phase 3 small molecule completed

    1 trial

  4. Losmapimod

    Fulcrum Therapeutics

    Facioscapulohumeral Muscular Dystrophy (FSHD)

    phase 3 small molecule terminated

    2 trials

  5. Losmapimod oral tablet

    Fulcrum Therapeutics

    COVID-19

    phase 3 small molecule terminated

    1 trial

  6. Low Frequency Right sided repetitive transcranial magnetic stimulation (LFR rTMS)

    United Therapeutics Europe Ltd

    TBI Depression

    phase 3 other completed

    1 trial

  7. Low-dose complex B-vitamins

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hyperhomocysteinemia

    phase 3 other completed

    1 trial

  8. Low-dose rtPA

    Takeda

    Ischemic Stroke

    phase 3 small molecule completed

    1 trial

  9. Lu AA21004

    Takeda

    Major Depressive Disorder

    phase 3 small molecule completed

    1 trial

  10. Lu AF35700

    H. Lundbeck A/S

    Treatment-resistant Schizophrenia

    phase 3 small molecule terminated

    1 trial

  11. Lubiprostone

    Takeda

    Constipation - Functional

    phase 3 small molecule completed

    1 trial

  12. Lubiprostone

    Takeda

    Irritable Bowel Syndrome With Constipation

    phase 3 small molecule completed

    1 trial

  13. Lucentis 10 mg/ml solution for injection, FARICIMAB

    Hoffmann-La Roche

    Choroidal neovascularization secondary to pathologic myopia

    phase 3 small molecule active

    1 trial

  14. Lucentis 10 mg/ml solution for injection, Ranibizumab

    CuraTeQ Biologics s.r.o

    wet macula degeneration

    phase 3 small molecule active

    1 trial

  15. Lucerastat

    Lacuna Pharma Pty Ltd

    Fabry disease

    phase 3 small molecule active

    1 trial

  16. Lucinactant

    WINDTREE THERAPEUTICS INC /DE/

    Meconium Aspiration

    phase 3 small molecule terminated

    1 trial

  17. Lumacaftor

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule completed

    6 trials

  18. Lumacaftor Plus Ivacaftor Combination

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation

    phase 3 small molecule completed

    1 trial

  19. Lumacaftor Plus Ivacaftor Combination

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis, Homozygous for the F508del CFTR Mutation

    phase 3 small molecule completed

    1 trial

  20. Lumasiran

    Alnylam Netherlands B.V.

    Primary Hyperoxaluria

    phase 3 small molecule completed

    1 trial

  21. Lumasiran

    Alnylam Netherlands B.V.

    Primary Hyperoxaluria Type 1

    phase 3 small molecule completed

    1 trial

  22. Lurasidone

    Sumitomo Pharma (Suzhou) Co.,

    Bipolar I Depression

    phase 3 small molecule completed

    1 trial

  23. Lutikizumab

    AbbVie

    Hidradenitis Suppurativa

    phase 3 small molecule active

    1 trial

  24. Lutikizumab, Placebo of Lutikizumab

    AbbVie Deutschland GmbH & Co. KG

    Hidradenitis Suppurativa

    phase 3 small molecule active

    1 trial

  25. Luveltamab tazevibulin

    SUTRO BIOPHARMA, INC.

    Ovarian Cancer

    phase 3 small molecule terminated

    1 trial

  26. Lynparza 100 mg film-coated tablets, ABIRATERONE , PREDNISOLONE , Lynparza 150 mg film-coated tablets

    AstraZeneca AB

    Metastatic castration-resistant prostate cancer

    phase 3 small molecule active

    1 trial

  27. Lynparza 100 mg film-coated tablets, Lynparza 150 mg film-coated tablets

    The George Institute

    Patients with a histological diagnosis of p53abn HREC, treated with curative intent, after surgery (hysterectomy and bilateral salpingooophorectomy, with or without lymphadenectomy or sentinel node biopsy), without signs of residual disease or distant metastases

    phase 3 small molecule active

    1 trial

  28. Lynparza 100 mg film-coated tablets, Placebo - film-coated tablets, Lynparza 150 mg film-coated tablets

    AstraZeneca AB

    Breast Cancer

    phase 3 small molecule active

    1 trial

  29. Lynparza 100 mg film-coated tablets, Sodium Chloride Intravenous Infusion BP 0.9% w/v Solution for Infusion (not authorised), Placebo film-coated tablet (Not Authorised), Lynparza 150 mg film-coated tablets, IMFINZI 50 mg/mL concentrate for solution for infusion., MYCOPHENOLATE MOFETIL, INFLIXIMAB, BEVACIZUMAB

    AstraZeneca AB

    Newly diagnosed advanced (FIGO stage III-IV) high grade epithelial ovarian, fallopian or primary peritoneal cancer

    phase 3 small molecule active

    1 trial

  30. Lynparza 150 mg film-coated tablets, IBRANCE 125 mg hard capsules, Lynparza 100 mg film-coated tablets, IMFINZI 50 mg/mL concentrate for solution for infusion., Tabrecta 200 mg film-coated tablets, Daurismo 100 mg film-coated tablets, Mekinist 0.5 mg film-coated tablets, Tabrecta 150 mg film-coated tablets, Lytgobi 4 mg film-coated tablets, Mekinist 2 mg film-coated tablets, IBRANCE 100 mg hard capsules, Tyverb 250 mg film-coated tablets, Tafinlar 75 mg hard capsules, Zykadia 150 mg hard capsules, IBRANCE 7

    The George Institute

    Unresectable locally advanced and/or metastatic soft-tissue sarcoma

    phase 3 small molecule active

    1 trial

  31. Lynparza 150 mg film-coated tablets, Lynparza 100 mg film-coated tablets

    AstraZeneca AB

    BRCA Mutated Ovarian Cancer Patients, Epithelian ovarian cancer, Metastatic Breast Cancer, Platinum Sensitive Relapsed Ovarian Cancer, Patients with gBRCA mutated metastatic pancreatic cancer, prostate cancer, endometrium cancer

    phase 3 small molecule active

    1 trial

  32. Lynparza 150 mg film-coated tablets, PACLITAXEL , CARBOPLATIN , GEMCITABINE , DOXORUBICIN , Lynparza 100 mg film-coated tablets, CISPLATIN , BEVACIZUMAB

    Fondazione Telethon ETS

    Recurrent ovarian cancer

    phase 3 small molecule active

    1 trial

  33. MAT2203

    Matinas BioPharma Holdings

    Cryptococcal Meningitis

    phase 3 small molecule active

    2 trials

  34. MB-102 DMID

    Hangzhou Zhongmei Huadong Pharmaceutical Co.,

    Kidney Diseases

    phase 3 small molecule completed

    1 trial

  35. MC0518, EVEROLIMUS, MYCOPHENOLIC ACID , ANTITHYMOCYTE IMMUNOGLOBULIN (RABBIT)

    Medac Gesellschaft fuer klinische Spezialpraeparate mbH

    Steroid refractory Acute Graft versus host Disease

    phase 3 small molecule active

    1 trial

  36. MCV-ACYW135 Vaccine Group

    Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

    Meningitis

    phase 3 mab completed

    1 trial

  37. MEDI4736

    AstraZeneca

    Squamous Cell Carcinoma of the Head and Neck

    phase 3 mab completed

    1 trial

  38. MEDI4736

    AstraZeneca

    Non-Small Cell Lung Cancer

    phase 3 small molecule completed

    1 trial

  39. MEDI4736 (Durvalumab)

    AstraZeneca

    Non-Small-Cell Lung Carcinoma NSCLC

    phase 3 mab active

    1 trial

  40. MEDI4736 Placebo, DURVALUMAB

    CERO THERAPEUTICS HOLDINGS, INC.

    Completely resected primary stage IB (≥ 4cm), II and IIIA non-small cell lung cancer patients

    phase 3 small molecule active

    1 trial

  41. MEDROXYPROGESTERONE , Opevesostat, EXEMESTANE , LETROZOLE , MEGESTROL , FLUDROCORTISONE , TAMOXIFEN , FULVESTRANT , HYDROCORTISONE , DEXAMETHASONE

    Merck Sharp and Dohme

    Breast cancer, Ovarian cancer, Endometrial cancer

    phase 3 small molecule active

    1 trial

  42. MELATONINE ARROW LP 2 mg, comprimé à libération prolongée, PLACEBO DE MELATONINE ARROW LP 2 mg comprimé

    Pari Pharma GmbH

    insomnia, Depressive episode

    phase 3 small molecule active

    1 trial

  43. MEP

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nasopharyngeal Carcinoma

    phase 3 small molecule terminated

    1 trial

  44. MEPOLIZUMAB

    GlaxoSmithKline

    Hypereosinophilic syndrome (HES)

    phase 3 small molecule active

    1 trial

  45. MESNA, MESNA, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Fludarabine Teva 25 mg/ml concentraat voor oplossing voor injectie of infusie, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Endoxan, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Endoxan 1000 mg milteliai injekciniam tirpalui, Proleukin 18 x 106 IE Poeder voor oplossing voor injectie of infusie, Cycloph

    Iovance Biotherapeutics B.V.

    Melanoma

    phase 3 small molecule active

    1 trial

  46. METFORMIN

    Pari Pharma GmbH

    Type 2 Diabetes complete remission after bariatric surgery under antidiabetic drug

    phase 3 small molecule active

    1 trial

  47. METFORMIN , DAPAGLIFLOZIN

    Eli Lilly Co.

    Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  48. METFORMIN, COLCHICINE

    Disc Medicine

    PASC: post-acute sequelae of SARS-CoV-2 infection

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many Phase III pipeline programs are in the directory?

5,427 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.